Equillium, Inc.

NASDAQ:EQ

0.72 (USD) • At close January 8, 2025
Bedrijfsnaam Equillium, Inc.
Symbool EQ
Munteenheid USD
Prijs 0.716
Beurswaarde 25,382,625
Dividendpercentage 0%
52-weken bereik 0.56 - 3.25
Industrie Biotechnology
Sector Healthcare
CEO Mr. Bruce D. Steel C.F.A.
Website https://equilliumbio.com

An error occurred while fetching data.

Over Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials

Vergelijkbare Aandelen

Fortress Biotech, Inc. logo

Fortress Biotech, Inc.

FBIO

2.08 USD

Celcuity Inc. logo

Celcuity Inc.

CELC

12.7 USD

Surrozen, Inc. logo

Surrozen, Inc.

SRZN

12.81 USD

Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc.

TRVI

4.03 USD

Aptose Biosciences Inc. logo

Aptose Biosciences Inc.

APTO

0.213 USD

iCAD, Inc. logo

iCAD, Inc.

ICAD

1.96 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)